ArticleFrontiers in medicine2026
Folate metabolism-based risk stratification identifies CYP27B1 as a determinant of tumor progression in HNSCC.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is characterized by frequent recurrence and poor survival, highlighting the need for reliable biomarkers for risk stratification and therapeutic guidance. Folate-mediated one-carbon metabolism has been linked to tumor development; however, its prognostic and immunological relevance in HNSCC remains unclear. Using The Cancer Genome Atlas (TCGA) transcriptomic data, we developed and validated a folate metabolism-related gene signature (FMRG_score). An 11-gene model constructed by least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression effectively stratified patients into distinct survival groups and served as an independent prognostic factor. A nomogram integrating FMRG_score with clinical variables demonstrated favorable predictive performance. Functional enrichment analyses revealed activation of oncogenic pathways in high-risk tumors. Immune deconvolution indicated that elevated FMRG_score was associated with reduced anti-tumor immune infiltration, increased macrophage-related signals, and an immunosuppressive tumor microenvironment. Drug response prediction suggested higher estimated IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.